(Q43650924)

English

Cost-utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myeloma

scientific article published in May 2001

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

25 November 2017

Cost-utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myeloma (English)

1 reference

Europe PubMed Central

25 November 2017

author name string

N Gulbrandsen

1

1 reference

Europe PubMed Central

25 November 2017

F Wisløff

2

1 reference

Europe PubMed Central

25 November 2017

E Nord

3

1 reference

Europe PubMed Central

25 November 2017

S Lenhoff

4

1 reference

Europe PubMed Central

25 November 2017

M Hjorth

5

1 reference

Europe PubMed Central

25 November 2017

J Westin

6

1 reference

Europe PubMed Central

25 November 2017

Nordic Myeloma Study Group

7

1 reference

Europe PubMed Central

25 November 2017

publication date

1 May 2001

1 reference

Europe PubMed Central

25 November 2017

European Journal of Haematology

1 reference

Europe PubMed Central

25 November 2017

66

1 reference

Europe PubMed Central

25 November 2017

5

1 reference

Europe PubMed Central

25 November 2017

328-336

1 reference

Europe PubMed Central

25 November 2017

Measurement of health-related quality of life in multiple myeloma. Nordic Myeloma Study Group.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.066005328.X

21 January 2018

Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone + alpha-interferon. The Nordic Myeloma Study Group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.066005328.X

21 January 2018

The friction cost method for measuring indirect costs of disease.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.066005328.X

21 January 2018

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.066005328.X

21 January 2018

Methods for quality adjustment of life years

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.066005328.X

21 January 2018

Social evaluation of health care versus personal evaluation of health states. Evidence on the validity of four health-state scaling instruments using Norwegian and Australian surveys

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.066005328.X

21 January 2018

The validity of using health state indexes in measuring the consequences of traffic injury for public health.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.066005328.X

21 January 2018

Health status index models for use in resource allocation decisions. A critical review in the light of observed preferences for social choice

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.066005328.X

21 January 2018

Toward quality assurance in QALY calculations

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.066005328.X

21 January 2018

A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.066005328.X

21 January 2018

Survival in conventionally treated younger (<60 years) multiple myeloma patients: no improvement during two decades. Nordic Myeloma Study Group (NMSG)

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.066005328.X

7 January 2021

based on heuristic

inferred from DOI database lookup

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.066005328.X

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon-alpha 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. A randomized, controlled trial. The Nordic Myeloma Study Group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.066005328.X

7 January 2021

based on heuristic

inferred from DOI database lookup

Cost-utility analysis of melphalan plus prednisone with or without interferon-alpha 2b in newly diagnosed multiple myeloma. Results from a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.066005328.X

7 January 2021

based on heuristic

inferred from DOI database lookup

Costs of intensive treatment and follow-up of patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.066005328.X

7 January 2021

based on heuristic

inferred from DOI database lookup

Cost-effectiveness of interferon alfa in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.066005328.X

7 January 2021

based on heuristic

inferred from DOI database lookup

Feasibility and cost-effectiveness of outpatient autotransplants in multiple myeloma

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.066005328.X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1034/J.1600-0609.2001.066005328.X

1 reference

Europe PubMed Central

25 November 2017

1 reference

Europe PubMed Central

25 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43650924&oldid=2102324565"